Mineralys Therapeutics (MLYS) is down -4.9%, or -$1.82 to $35.28.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
- Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
- Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position
- Mineralys announces new subgroup analyses from Phase 3 Launch-HTN trial
- Mineralys Therapeutics Announces Public Offering of Shares